Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials

Siyuan Yang1 · Jiahe Wang1 · Xiang Li1 · Tianyi Wang1 · Zhongmou Xu1 · Xiang Xu1 · Xinmin Zhou2 · Gang Chen1

Accepted: 6 December 2020 / Published online: 7 January 2021
© The Author(s) 2021

Abstract
Esketamine is a promising drug which can induce antidepressant effects in Major Depression Disorder (MDD). Several randomized controlled trials (RCTs) have been implemented to assess the efficacy and safety of esketamine for the treatment of MDD. Therefore, we carried out a meta-analysis to assess adverse effect profiles of esketamine for the treatment of MDD. We searched RCTs which were implemented from January 2010 to June 2020 by searching PubMed, Embase and Cochrane Library databases. Finally, four RCTs with 551 patients were included in our study. We pooled 551 patients from 4 RCTs. Compared with placebo, an increased risk of adverse effects was observed in our analysis. After using esketamine, the risk of nausea (RR = 2.34, 95% CI, 1.04 to 5.25, \( P = 0.04 \)), dissociation (RR = 4.54, 95% CI, 2.36 to 8.73, \( P < 0.00001 \)), dizziness (RR = 3.00, 95% CI, 1.80 to 5.00, \( P < 0.0001 \)), vertigo (RR = 7.47, 95% CI, 2.55 to 21.86, \( P = 0.0002 \)), hypoesthesia (RR = 5.68, 95% CI, 2.06 to 15.63, \( P = 0.0008 \)), sedation (RR = 3.96, 95% CI, 1.29 to 12.15, \( P = 0.02 \)) and paresthesia (RR = 3.05, 95% CI, 1.07 to 8.65, \( P = 0.04 \)) were significantly increased compared with placebo. Our synthesized data analysis revealed drug specific risk profiles. The most frequent adverse effects under treatment with esketamine were nausea, dissociation, dizziness, vertigo, hypoesthesia, sedation and paresthesia.

Keywords Esketamine · Major depression disorder · Adverse effects · Meta-analysis
Introduction

Major depressive disorder (MDD) is a chronic mental disease which may lead to disability and the population of people who suffer from MDD is about 20% of the world population [1]. MDD is also projected to be the main cause of burden of disorder in developed countries by 2030 [2]. MDD is a main reason of morbidity worldwide and is associated with psychosocial and functional impairment, cognitive dysfunction, high risk of suicidal behaviors and excess mortality [3–6]. Major depression disorder is the psychiatric diagnosis most associated with suicide [7]. There are some limitations in currently antidepressant treatment such as delayed onset of efficacy. Approximately one-third of patients with MDD fail to get relief from depression, though they have used multiple biogenic amine antidepressants and thus they get treatment-resistant depression (TRD). Therefore, we need to develop alternate antidepressants which can cause rapid and long-term relief of depressive symptoms to solve the problem of high levels of treatment resistance [8].

Recently, esketamine has been approved as a nasal spray formulation for the treatment of MDD in the American [9]. Proof-of-concept single-dose and repeat-dose studies with intravenous esketamine has shown a significant antidepressant effect and can reduce the risk of suicidal behavior in the short term, with response rates over 60% as early as 4.5 h after a single dose, with a sustained effect after 24 h, and over 40% after 7 days [10]. Esketamine effect can exist continuously over several weeks with repeated doses (two to three doses per week). Intranasal esketamine has shown great efficacy in the treatment of depression and has been granted as a ‘breakthrough therapy’ medicine by US FDA. Theoretically it may offer an improved tolerability profile compared with other antidepressants [11]. Although esketamine has been proved efficient in the treatment of MDD, it also causes some adverse effects. Therefore, we performed a study which included four randomized controlled trials (RCTs) to carry out a comprehensive analysis of adverse effects of the esketamine for the treatment of MDD.

Methods

Search Strategy

PubMed, Embase, and Cochrane Library were systematically searched from January 2010 to June 2020 using the following terms: [(“esketamine, major depression disorder.”)] to find the studies we need. Besides, we guaranteed this meta-analysis had included all relevant studies by carefully checking reference documents from studies we chose. We implemented a meta-analysis of data from four published trials according to the PRISMA guidelines.

Inclusion and Exclusion Criteria

Inclusion criteria indicated as below: (a) Study form: randomized controlled trials; (b) Language limitation: our research had no language limitation; (c) Participants: people who are 18–64 years old with major depression disorder and have no response to at least 1 antidepressant in the depression; (d) Intervention: esketamine and placebo; (e) Outcomes: adverse effects that patients experienced during these studies. Exclusion criteria indicated as below: (a) study forms: case reports, reviews, retrospective studies, protocols and cohort studies; (b) patients as below were excluded: patients with depressive symptoms to esketamine, people who have
allergies, hypersensitivity, intolerance or contraindication to esketamine and who have received VNS or DBS, patients who have a current DSM-IV-TR diagnosis of bipolar and related disorders, intellectual disability or cluster b personality disorder, patients who have a current or prior DSM-IV-TR diagnosis of a psychotic disorder, MDD with psychosis, post-traumatic stress disorder (PTSD) or obsessive compulsive disorder (OCD), patients with history of moderate or severe substance or alcohol use disorder.

**Study Selection and Data Collection**

All studies that we found in these three databases had been evaluated by inclusion and exclusion criteria that had mentioned. After carefully choosing, the basic information of these studies, the number of patients the study included, and the occurrence side effects were extracted (Table 1).

**Outcome Measures**

Adverse effects that patients experienced included nausea, dissociation, dizziness, vertigo, headache, hypoesthesia, dysgeusia, somnolence, sedation, anxiety, euphoric mood and paresthesia.

**Subgroup Analysis**

By analyzing the distinguishing feature of studies included in this meta-analysis, two subgroup analyses were implemented as below: 1. different doses of esketamine; 2. different ways of administration of esketamine. Dosage of intranasal esketamine was divided into 28 mg, 56 mg and 84 mg and dosage of intravenous esketamine was divided into 20 mg/kg and 40 mg/kg. Different ways of administration can be intranasal and intravenous.

**Summary Measures and Synthesis of Results**

Review manager 5.3 was used to assess the data. Risk ratios (RRs) with 95%CI based on the random effects model were used to clarify the differences in the incidences of adverse effects. The statistical heterogeneity was evaluated by the $I^2$ statistic as below: the heterogeneity of $I^2 < 30\%$ is low, the heterogeneity of $30\% < I^2 < 50\%$ is moderate and the heterogeneity of $I^2 > 50\%$ is substantial. The stability of the consolidated results is evaluated by subgroup analysis. A $P < 0.05$ value was significant for all analyses.

**Risk of Bias**

We used the Review Manager 5.3 software to explore the risk of bias in these studies included. The Cochrane collaboration uniform criteria were used to assess the risk of bias of RCTs.

**Results**

**Search Results**

Five hundred sixty-six articles from PubMed and Embase, and 112 from Cochrane library were identified. 434 articles were left after articles that duplicates were removed, and 284
| Trials                  | Maggie Fedgchin, 2019 NCT02417064 | Ella J. Daly, 2018 NCT01998958 | Carla M Canuso, 2018 NCT02133001 | Jaskaran B Singh, 2016 NCT01640080 |
|------------------------|-----------------------------------|--------------------------------|----------------------------------|----------------------------------|

### Information of the Included Trials

| Regions                  | multicenter in USA               | multicenter in USA               | multicenter in USA               | multicenter in USA               |
|--------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Phases                   | III                             | III                             | III                             | III                             |

### Eligibility Criteria and Study Design

#### Inclusion Criteria

- 18–64 years old with recurrent MDD or single-episode MDD (≥2 years), IDS-C30 total score ≥ 34

#### Exclusion Criteria

- Depressive symptoms to esketamine
- VNS or DBS
- DSM-5 diagnosis of a psychotic disorder with a history of moderate or severe substance or alcohol use disorder

### Study Design and The Number of Subjects

- esketamine [56 mg]/oral antidepressant
- esketamine [84 mg]/oral antidepressant
- esketamine [84 mg]/oral antidepressant/placebo

### Outcomes Assessments

#### Primary outcomes

- Change from Baseline in MADRS Total Score
  - up to Day 28 (MMRM Analysis + ANCOVA Analysis)

#### Safety outcomes

- Nausea, dissociation, Dizziness, Vertigo, Headache, Hypoesthesia, Dysgeusia, Vomiting, Anxiety, Somnolence, Euphoric mood, sedation

---

MDD, major depression disorder; VNS, vagal nerve stimulation; DBS deep brain stimulation; DSM the Diagnostic and Statistical Manual of Mental Disorders; MADRS Montgomery-Asberg Depression Rating Scale
articles which were not relevant to the subject were removed. Thus, 150 of these articles related to the topic of interest were left. However, among them, 113 articles were excluded because they were protocols, case report, reviews and comments. Besides, 33 articles on subgroup analysis of RCTs were excluded. Therefore, finally, we included these 4 RCTs in our study (Fig. 1).

**Assessment of Adverse Events**

We analyzed several adverse events, including nausea, dissociation, dizziness, vertigo, headache, hypesthesia, dysgeusia, somnolence and sedation. We divided these adverse effects into three parts (head discomfort, psychiatric symptoms and other symptoms) to display. In esketamine group, the incidence of nausea, dissociation, dizziness, vertigo, hypesthesia, somnolence or sedation is higher than the placebo group, while the proportion of headache and dysgeusia have no significant difference (head discomfort: dizziness: \( RR = 3.00, 95\% CI, 1.80 \text{ to } 5.00, P < 0.0001 \); vertigo: \( RR = 7.47, 95\% CI, 2.55 \text{ to } 21.86, P = 0.0002 \); headache: \( RR = 1.28, 95\% CI, 0.88 \text{ to } 1.86, P = 0.19 \) (Fig. 2), psychiatric symptoms: dissociation: \( RR = 4.54, 95\% CI, 2.36 \text{ to } 8.73, P < 0.0001 \); somnolence: \( RR = 1.73, 95\% CI, 1.02 \text{ to } 2.95, P = 0.04 \); sedation: \( RR = 3.96, 95\% CI, 1.29 \text{ to } 12.15, P = 0.02 \) (Fig. 3), other symptoms: hypesthesia: \( RR = 5.68, 95\% CI, 2.06 \text{ to } 15.63, P = 0.0008 \); dysgeusia: \( RR = 1.13, 95\% CI, 0.75 \text{ to } 1.70, P = 0.55 \); nausea: \( RR = 2.34, 95\% CI, 1.04 \text{ to } 5.25, P = 0.04 \); (Fig. 4a) anxiety: \( RR = 1.94, 95\% CI, 0.57 \text{ to } 6.44, P = 0.22 \); euphoric mood: \( RR = 2.11, 95\% CI, 0.70 \text{ to } 6.36, P = 0.77 \); paresthesia: \( RR = 3.05, 95\% CI, 1.07 \text{ to } 8.65, P = 0.84 \); (Fig. 4b).

**Subgroup Analysis**

By analyzed previous clinical trials we chose, the dosage of intranasal esketamine were roughly divided into 28 mg, 56 mg and 84 mg. In 28 mg subgroup, it has no significant difference in adverse effects listed in the article (nausea: \( P = 0.87 \), dissociation: \( P = 0.30 \), dizziness: \( P = 0.07 \), vertigo: \( P = 0.16 \), headache: \( P = 0.05 \), somnolence: \( P = 0.16 \), sedation: \( P = 0.31 \), hypesthesia: \( P = 0.31 \), dysgeusia: \( P = 0.35 \), Paresthesia: \( P = 0.15 \) ). In 56 mg and 84 mg subgroup, the proportion of patients who have nausea (56 mg: \( RR = 2.48, 95\% CI, 1.41 \text{ to } 4.35, P = 0.002 \); 84 mg: \( RR = 3.23, 95\% CI, 1.91 \text{ to } 5.49, P < 0.0001 \)), dissociation (56 mg: \( RR = 8.06, 95\% CI, 3.27 \text{ to } 19.91, P < 0.00001 \); 84 mg: \( RR = 4.77, 95\% CI, 2.03 \text{ to } 11.23, P = 0.0003 \)), dizziness (56 mg: \( RR = 4.69, 95\% CI, 1.31 \text{ to } 16.73, P = 0.02 \); 84 mg: \( RR = 3.21, 95\% CI, 1.53 \text{ to } 6.75, P = 0.002 \)), vertigo (56 mg: \( RR = 10.16, 95\% CI, 2.78 \text{ to } 37.04, P = 0.0004 \); 84 mg: \( RR = 9.91, 95\% CI, 3.04 \text{ to } 32.26, P = 0.0001 \)), hypesthesia (56 mg: \( RR = 8.0, 95\% CI, 2.19 \text{ to } 29.45, P = 0.002 \); 84 mg: \( RR = 7.17, 95\% CI, 2.39 \text{ to } 21.56, P = 0.0005 \)), sedation (56 mg: \( RR = 6.55, 95\% CI, 1.17 \text{ to } 36.51, P = 0.03 \); 84 mg: \( RR = 4.09, 95\% CI, 1.30, 36.51, P = 0.02 \) or paresthesia(56 mg: \( RR = 7.00, 95\% CI, 2.18 \text{ to } 22.43, P = 0.001 \); 84 mg: \( RR = 4.07, 95\% CI, 1.21, 13.70, P = 0.02 \) ) in esketamine group is more than the placebo group. From these data, we found the most common adverse effects under treatment with esketamine were vertigo, dissociation, hypesthesia, dizziness and nausea. However, in 56 mg and 84 mg subgroup, it has no significant difference in headache, dysgeusia and somnolence (headache: 56 mg: \( RR = 1.24, 95\% CI, 0.74 \text{ to } 2.07, P = 0.42 \); 84 mg: \( RR = 1.27, 95\% CI, 0.83 \text{ to } 1.95, P = 0.27 \); dysgeusia: 56 mg: \( RR = 0.92, 95\% CI, 0.53 \text{ to } 1.60, P = 0.77 \); 84 mg: \( RR = 1.34, 95\% CI, 0.86 \text{ to } 2.10, P = 0.20 \), somnolence: 56 mg: \( RR = 1.81, 95\% CI, 0.97 \text{ to } 3.38, P = 0.06 \); 84 mg: \( RR = 1.60, 95\% CI, 0.88 \text{ to } 2.90, P = 0.12 \), anxiety: 56 mg:
RR = 1.44, 95% CI, 0.53 to 3.93, P = 0.47; 84 mg: RR = 1.86, 95% CI, 0.76 to 4.52, P = 0.19, euphoric mood: 56 mg: RR = 4.15, 95% CI, 0.86 to 19.99, P = 0.98; 84 mg: RR = 0.97, 95% CI, 0.13 to 7.03, P = 0.12).

The administration of esketamine included two ways: intranasal and intravenous. Intravenous esketamine has no significant difference in safety compared with the placebo group (nausea: RR = 0.71, 95% CI, 0.17 to 3.03, P = 0.65, dissociation: RR = 3.33, 95% CI, 0.20 to 54.64, P = 0.40, dizziness: RR = 1.28, 95% CI, 0.07 to 24.76, P = 0.87, vertigo: RR = 1.28,
**a headache**

| Study or Subgroup | Esketamine Events Total | Placebo Events Total | Risk Ratio M.H. Random, 95% CI |
|-------------------|------------------------|---------------------|--------------------------------|
| Carla M Canuso 2018 | 11 | 35 | 8 | 31 | 23.3% | 1.22 [0.56, 2.64] |
| Ella J Daly 2016 | 12 | 56 | 3 | 33 | 9.8% | 2.36 [0.72, 7.75] |
| Jaskaran B Singh 2016 | 9 | 42 | 2 | 10 | 7.4% | 1.07 [0.27, 4.21] |
| Maggie Fedgchin 2019 | 47 | 231 | 19 | 113 | 59.5% | 1.21 [0.75, 1.96] |

Total (95% CI): 364 187 100.0% 1.28 [0.88, 1.86]

Total events: 79 32

Heterogeneity: Tau² = 0.00, Chi² = 1.15, df = 3 (P = 0.76); I² = 0%

Test for overall effect: Z = 1.31 (P = 0.19)

**b dizziness**

| Study or Subgroup | Esketamine Events Total | Placebo Events Total | Risk Ratio M.H. Random, 95% CI |
|-------------------|------------------------|---------------------|--------------------------------|
| Carla M Canuso 2018 | 12 | 35 | 4 | 31 | 24.9% | 2.66 [0.86, 7.39] |
| Ella J Daly 2016 | 20 | 56 | 1 | 33 | 6.8% | 11.79 [1.66, 83.82] |
| Jaskaran B Singh 2016 | 2 | 42 | 0 | 10 | 3.0% | 1.26 [0.07, 24.76] |
| Maggie Fedgchin 2019 | 58 | 231 | 10 | 113 | 85.5% | 2.84 [1.51, 5.34] |

Total (95% CI): 364 187 100.0% 3.00 [1.80, 5.00]

Total events: 92 15

Heterogeneity: Tau² = 0.00, Chi² = 2.41, df = 3 (P = 0.49); I² = 0%

Test for overall effect: Z = 4.22 (P < 0.0001)

**c vertigo**

| Study or Subgroup | Esketamine Events Total | Placebo Events Total | Risk Ratio M.H. Random, 95% CI |
|-------------------|------------------------|---------------------|--------------------------------|
| Carla M Canuso 2018 | 4 | 35 | 0 | 31 | 13.9% | 8.00 [0.45, 142.98] |
| Ella J Daly 2016 | 4 | 56 | 0 | 33 | 13.8% | 5.37 [0.30, 96.66] |
| Jaskaran B Singh 2016 | 2 | 42 | 0 | 10 | 13.1% | 1.28 [0.07, 24.76] |
| Maggie Fedgchin 2019 | 48 | 231 | 2 | 113 | 59.2% | 11.74 [2.91, 47.44] |

Total (95% CI): 364 187 100.0% 7.47 [2.55, 21.86]

Total events: 58 2

Heterogeneity: Tau² = 0.00, Chi² = 1.99, df = 3 (P = 0.60); I² = 0%

Test for overall effect: Z = 3.67 (P = 0.0002)

**Fig. 2** The pooled RR of head discomfort. The blue square indicates the estimated RR for each RCT. The size of blue square indicates the estimated weight of each RCT, and the extending lines indicate the estimated 95% CI of RR for each RCT. The black diamond indicates the estimated RR (95% CI) for all patients together. (a) Headache (b) Dizziness (c) Vertigo. CI, confidence interval; RCT, randomized controlled trial; RR: risk ratio

95% CI, 0.07 to 24.76, P = 0.87, headache: RR = 1.07, 95% CI, 0.27 to 4.21, P = 0.92, hypoesthesia: RR = 1.28, 95% CI, 0.07 to 24.76, P = 0.87, paresthesia: RR = 1.30, 95% CI, 0.06 to 29.10, P = 0.87). In the intranasal esketamine, the proportion of people who have nausea, dissociation, dizziness, vertigo or hypoesthesia in esketamine group is more than the placebo group. However, the proportion of people who have headache and paresthesia (RR = 1.30, 95% CI, 0.88, 1.92, P = 0.18) in esketamine group has no significant difference (Table 2).

**Risk of Bias in Included Studies**

The risk of bias of the four included RCTs is shown in Fig. 5. The risk for performance bias is unclear in Carla’s study in 2018. The risk for attrition bias is unclear in Carle’s study in 2018 and Ella’s study in 2016. The risk for reporting bias is unclear in Ella’s study in 2016 and Jaskaran’s study in 2016.
## Discussion

Our study included 551 patients from 4 RCTs which supplied high levels of clinical reliability to our study to assess the adverse effects of esketamine for the treatment of Major Depression Disorder [12]. In recent years, some studies had comprehensively described the adverse effects of esketamine. The study performed by Ella had reported the adverse effects that occurred in more than 10% of all the patients included dizziness (39%), dysgeusia (23%), nausea (16%), headache (14%) and sedation (11%). However, adverse events were inconsistent in these RCTs. After our study, we found that the most common adverse effects under treatment with esketamine were vertigo, hypoesthesia, dissociation, sedation, dizziness, nausea and paresthesia followed by headache, somnolence, dysgeusia, anxiety and euphoric mood. During subgroup analysis, we found the incidence of adverse events showed no statistical significance in patients whose dosage of esketamine was 28 mg. In 56 mg and 84 mg subgroup, there was a significantly increase in the incidence of adverse events such as dissociation, vertigo, dizziness, nausea, hypoesthesia, sedation and paresthesia compared with the placebo group. We

### Fig. 3

The pooled RR of psychiatric symptoms. The blue square indicates the estimated RR for each RCT. The size of blue square indicates the estimated weight of each RCT, and the extending lines indicate the estimated 95% CI of RR for each RCT. The black diamond indicates the estimated RR (95% CI) for all patients together. (a) Dissociation (b) Somnolence (c) Sedation. CI, confidence interval; RCT, randomized controlled trial; RR: risk ratio

### Table 1

| Study or Subgroup | Esketamine | Placebo | Risk Ratio | Risk Ratio |
|-------------------|------------|---------|------------|------------|
| Events            | Total      | Events  | Total      | M-H, Random, 95% CI |
| Carla M Canuso 2018 | 11         | 35      | 4          | 31         | 39.8% | 2.44 [0.86, 6.87] |
| Ella J Daly 2016   | 11         | 56      | 1          | 33         | 10.7% | 6.48 [0.88, 47.98]|
| Jaskaran B Singh 2016 | 6        | 42      | 0          | 10         | 5.5%  | 3.33 [0.20, 54.64]|
| Maggie Fedgchin 2019 | 62       | 231     | 4          | 113        | 44.1% | 7.58 [2.63, 20.32]|
| Total (95% CI)    | 364        | 187     | 100        | 4.54 [2.36, 8.73] |
| Total events      | 90         |         | 9          |            |        |            |

Heterogeneity: Tau² = 0.00, Chi² = 2.81, df = 3 (P = 0.42); I² = 0% Test for overall effect: Z = 4.65 (P = 0.00001)

### Table 2

| Study or Subgroup | Esketamine | Placebo | Risk Ratio | Risk Ratio |
|-------------------|------------|---------|------------|------------|
| Events            | Total      | Events  | Total      | M-H, Random, 95% CI |
| Carla M Canuso 2018 | 4          | 35      | 2          | 31         | 10.7% | 1.77 [0.35, 9.01] |
| Ella J Daly 2016   | 2          | 56      | 0          | 33         | 3.1%  | 2.98 [0.15, 60.30]|
| Maggie Fedgchin 2019 | 45        | 231     | 13         | 113        | 86.1% | 1.69 [0.95, 3.01] |
| Total (95% CI)    | 322        | 177     | 100        | 1.73 [1.02, 2.95] |
| Total events      | 51         |         | 15         |            |        |            |

Heterogeneity: Tau² = 0.00, Chi² = 0.13, df = 2 (P = 0.94); I² = 0% Test for overall effect: Z = 2.02 (P = 0.04)

### Table 3

| Study or Subgroup | Esketamine | Placebo | Risk Ratio | Risk Ratio |
|-------------------|------------|---------|------------|------------|
| Events            | Total      | Events  | Total      | M-H, Random, 95% CI |
| Carla M Canuso 2018 | 6          | 35      | 2          | 31         | 54.0% | 2.66 [0.58, 12.22]|
| Ella J Daly 2016   | 4          | 56      | 0          | 33         | 15.0% | 5.37 [0.30, 96.66]|
| Maggie Fedgchin 2019 | 14       | 231     | 1          | 113        | 30.9% | 6.85 [0.91, 51.43]|
| Total (95% CI)    | 322        | 177     | 100        | 3.96 [1.29, 12.15] |
| Total events      | 24         |         | 3          |            |        |            |

Heterogeneity: Tau² = 0.00, Chi² = 0.63, df = 2 (P = 0.73); I² = 0% Test for overall effect: Z = 2.40 (P = 0.02)
**Psychiatric Quarterly (2022) 93:81–95**

**Fig. 4** (a) The pooled RR of adverse events of sensory system symptoms. The blue square indicates the estimated RR for each RCT. The size of blue square indicates the estimated weight of each RCT, and the extending lines indicate the estimated 95% CI of RR for each RCT. The black diamond indicates the estimated RR (95% CI) for all patients together. (A) Dysgeusia (B) Hypoesthesia (C) Nausea. CI, confidence interval; RCT, randomized controlled trial; RR: risk ratio. (b) The pooled RR of adverse events of sensory system symptoms. The blue square indicates the estimated weight of each RCT, and the extending lines indicate the estimated 95% CI of RR for each RCT. The black diamond indicates the estimated RR (95% CI) for all patients together. (A) Anxiety (B) Euphoric mood (C) Paresthesia. CI, confidence interval; RCT, randomized controlled trial; RR: risk ratio

---

**Table 4**

| Study or Subgroup | Esisketamine Events | Placebo Events | Total Events | Weight | Risk Ratio M.H. Random, 95% CI |
|-------------------|---------------------|---------------|--------------|--------|--------------------------------|
| **A. Hypoesthesia** |                     |               |              |        |                                |
| Carla M. Canuso 2018 | 6                   | 35            | 41           | 0.21   | 5.31 [0.68, 41.74]             |
| Ella J. Daly 2018   | 7                   | 56            | 63           | 0.31   | 8.99 [0.33, 111.77]            |
| Jaskaran B Singh 2016 | 2               | 42            | 44           | 0.26   | 1.20 [0.07, 24.78]             |
| Maggie Fedgchin 2019 | 30               | 231           | 261          | 0.50   | 7.34 [1.79, 30.18]             |
| **Total (95% CI)** | 364                | 187           | 551          | 0.01   | 5.39 [2.08, 15.95]             |
| **B. Dysgeusia**    |                     |               |              |        |                                |
| Carla M. Canuso 2018 | 37                  | 231           | 268          | 0.61   | 1.09 [0.63, 1.81]              |
| Ella J. Daly 2018   | 10                  | 56            | 66           | 0.24   | 0.94 [0.25, 3.24]              |
| Maggie Fedgchin 2019 | 11               | 25            | 36           | 0.32   | 1.95 [0.78, 4.99]              |
| **Total (95% CI)** | 322                | 177           | 499          | 0.01   | 1.13 [0.75, 1.70]              |
| **C. Nausea**       |                     |               |              |        |                                |
| Carla M. Canuso 2018 | 3                   | 56            | 59           | 0.31   | 11.51 [0.69, 193.63]           |
| Ella J. Daly 2018   | 10                  | 33            | 43           | 0.29   | 1.69 [0.58, 6.03]              |
| Jaskaran B Singh 2016 | 6               | 20            | 26           | 0.29   | 0.71 [0.17, 3.03]              |
| Maggie Fedgchin 2019 | 68               | 231           | 299          | 0.50   | 2.47 [1.07, 5.74]              |
| **Total (95% CI)** | 364                | 187           | 551          | 0.01   | 2.34 [1.04, 5.25]              |

---

**Table 5**

| Study or Subgroup | Esisketamine Events | Placebo Events | Total Events | Weight | Risk Ratio M.H. Random, 95% CI |
|-------------------|---------------------|---------------|--------------|--------|--------------------------------|
| **A. Anxiety**    |                     |               |              |        |                                |
| Carla M. Canuso 2018 | 19                  | 231           | 250          | 0.40   | 3.31 [0.56, 2.17]              |
| Maggie Fedgchin 2019 | 6                   | 35            | 41           | 0.25   | 5.31 [0.68, 41.74]             |
| **Total (95% CI)** | 266                | 144           | 410          | 0.05   | 1.92 [0.97, 6.40]              |
| **B. Euphoric mood** |                  |               |              |        |                                |
| Maggie Fedgchin 2019 | 10                 | 231           | 241          | 0.48   | 2.45 [0.54, 10.80]             |
| Carla M. Canuso 2018 | 4                   | 35            | 39           | 0.23   | 1.77 [0.32, 9.21]              |
| **Total (95% CI)** | 280                | 144           | 424          | 0.05   | 2.11 [0.76, 6.30]              |
| **C. Paresthesia** |                     |               |              |        |                                |
| Carla M. Canuso 2018 | 6                   | 35            | 41           | 0.26   | 5.31 [0.68, 41.74]             |
| Ella J. Daly 2018   | 8                   | 112           | 120          | 0.33   | 6.12 [0.30, 128.36]            |
| Jaskaran B Singh 2016 | 2              | 42            | 44           | 0.26   | 1.28 [0.07, 24.79]             |
| Maggie Fedgchin 2019 | 10               | 231           | 241          | 0.48   | 2.45 [0.54, 10.80]             |
| **Total (95% CI)** | 436                | 187           | 623          | 0.05   | 2.57 [1.67, 8.85]              |

---

Test for overall effect: Z = 2.26 (P = 0.024)
### Table 2  Subgroup analyses of safety outcome

|                  | Nausea | Dissociation | Dizziness | Vertigo |
|------------------|--------|--------------|-----------|---------|
|                  | RR, 95%CI | P value | RR, 95%CI | P value | RR, 95%CI | P value | RR, 95%CI | P value |
| **Dose(intranasal)** |        |           |           |         |           |         |           |         |
| 28 mg             | 1.16 [0.21, 6.32] | 0.87 | 3.47 [0.34, 35.82] | 0.30 | 6.95 [0.84, 57.73] | 0.07 | 8.50 [0.43, 168.30] | 0.16 |
| 56 mg             | 2.48 [1.41, 4.35] | 0.002 | 8.06 [3.27, 19.91] | <0.0001 | 4.69 [1.31, 6.73] | 0.02 | 10.16 [2.78, 37.04] | 0.0004 |
| 84 mg             | 3.23 [1.91, 5.49] | <0.0001 | 4.77 [2.03, 11.23] | 0.003 | 3.21 [1.53, 6.75] | 0.002 | 9.91 [3.04, 32.26] | 0.0001 |
| **Subgroup Difference** | p = 0.47 | p = 0.64 | p = 0.74 | p = 0.99 |
| Intranasal        | 2.93 [1.58, 5.45] | 0.0007 | 4.64 [2.03, 10.63] | 0.0003 | 3.10 [1.81, 5.32] | <0.0001 | 9.75 [3.08, 30.87] | 0.001 |
| Intravenous       | 3.33 [0.20, 54.64] | 0.40 | 3.33 [0.20, 54.64] | 0.40 | 1.28 [0.07, 24.76] | 0.87 | 1.28 [0.07, 24.76] | 0.87 |
| **Subgroup Difference** | p = 0.08 | p = 0.82 | p = 0.56 | p = 0.21 |
| **Safety**        |        |           |           |         |           |         |           |         |
| **Dose(intranasal)** |        |           |           |         |           |         |           |         |
| 28 mg             | N/A | N/A | N/A | N/A | 9.57 [0.44, 210.54] | 0.15 |
| 56 mg             | 1.44 [0.53, 3.93] | 0.47 | 4.15 [0.86, 19.99] | 0.98 | 7.00 [2.18, 22.43] | 0.001 |
| 84 mg             | 1.86 [0.76, 4.52] | 0.19 | 0.97 [0.13, 7.03] | 0.08 | 4.07 [1.21, 13.70] | 0.02 | P < 0.0001 |         |
| **Subgroup Difference** | p = 0.71 | p = 0.12 | p = 0.12 | p = 0.12 |
| Intranasal        | N/A | N/A | N/A | N/A | 2.90 [0.72, 11.75] | 0.13 |
| Intravenous       | N/A | N/A | N/A | N/A | 1.30 [0.06, 29.10] | 0.87 | p = 0.82 | p = 0.15 |
| Dose (intranasal) | Headache RR, 95%CI | Hypoesthesia RR, 95%CI | Dysgeusia RR, 95%CI | Somnolence RR, 95%CI | Sedation RR, 95%CI |
|------------------|---------------------|------------------------|---------------------|----------------------|-------------------|
| 28 mg            |                     |                        |                     |                      |                   |
|                  | 3.47 [0.98, 12.32]  | 5.10 [0.22, 119.32]    | 0.50 [0.11, 2.15]   | 8.50 [0.43, 168.30]  | 5.10 [0.22, 119.32] |
|                  | 0.05                | 0.31                   | 0.35                | 0.16                 | 0.31              |
| 56 mg            |                     |                        |                     |                      |                   |
|                  | 1.24 [0.74, 2.07]   | 8.02 [2.19, 29.45]     | 0.92 [0.53, 1.60]   | 1.81 [0.97, 3.38]    | 6.55 [1.17, 36.51] |
|                  | 0.42                | 0.002                  | 0.77                | 0.06                 | 0.03              |
| 84 mg            |                     |                        |                     |                      |                   |
|                  | 1.27 [0.83, 1.95]   | 7.17 [2.39, 21.56]     | 1.34 [0.86, 2.10]   | 1.60 [0.88, 2.90]    | 4.09 [1.30, 36.51] |
|                  | 0.27                | 0.0005                 | 0.20                | 0.12                 | 0.02              |

Subgroup Difference
- Intranasal: p = 0.31
- Intravenous: N/A

Safety

| Dose (intranasal) | Psychiatric Quarterly (2022) 93:81–95 | N/A |
|------------------|---------------------------------------|-----|
| 28 mg            |                                       | N/A |
| 56 mg            |                                       | N/A |
| 84 mg            |                                       | N/A |

Subgroup Difference
- Intranasal
- Intravenous

Subgroup Difference
also found the incidence of adverse events in 56 mg and 84 mg showed no significant
difference except nausea, dissociation, dizziness, vertigo, hypoesthesia, sedation and paresthesia. For this reason, dose-related safety events were not found except nausea, dissociation, dizziness, vertigo, hypoesthesia, sedation and paresthesia. However, these RCTs assessed only the short-term adverse events of esketamine, we evaluated adverse events in these studies only in 4 weeks after the first evaluations of these studies on adverse events were limited to 4 weeks after the first dose. Therefore, whether esketamine will produce long-term adverse events or not still needs further observation and verification. Thus, we should pay attention to these short-term adverse events especially vertigo, dissociation, hypoesthesia, sedation, nausea, dizziness and paresthesia in the process of treatment for MDD with esketamine. We also found most adverse events occurring on dosing days were transient and either mild or moderate in severity, so we can pay more attention to adverse events on dosing days, but we also should care these adverse events after dosing days.

We also compared the incidence of adverse events of different ways of administration of esketamine: intranasal and intravenous. Intravenous studies were dosed by weight whereas intranasal studies were not. In the intranasal esketamine subgroup, we found intranasal esketamine mostly caused nausea, dissociation, dizziness, vertigo and hypoesthesia. However, due to the number of RCTs is not enough, the data we analyzed was not effective, we could not draw a clear conclusion in the intravenous
esketamine subgroup, but it would be worthwhile for future studies to shed light on the actual difference in safety between intranasal and intravenous esketamine. What is more, a study has been designed to investigate repeated administration of oral esketamine in patients with TRD. Therefore, we can study the advantages of different ways of treatment strategies of MDD in the future [13].

Our study also has a few limitations. Although patients in these studies used antidepressants before, all these studies we selected lacked the comparison of esketamine with other therapeutic medications. In the future, more studies are needed to compare whether esketamine is more effective than other therapeutic medications. When assessing difference of adverse effect in different ways of administration of esketamine, there is not enough study in intravenous esketamine. The single small intravenous esketamine double-blind placebo-controlled study is obviously too small to comment reliably on any differences from the intranasal studies. This is a very small study adds little to the data and its inclusion is questionable. Therefore, the accuracy of the results needs further verification. Thus, more studies are needed for assessing the safety, efficacy and tolerability of intranasal esketamine and intravenous esketamine. Moreover, the small sample size and enrollment criteria that excluded individuals with a history of psychotic symptoms and other situations limit some study findings. Therefore, in order to prove that the extensive application of esketamine on different kinds of people, more studies on MDD patients of different characteristics are still needed.

**Conclusions**

Because of the meta-analytic comparison between esketamine and placebo, our study revealed drug specific risk profiles and incidence of adverse effects in different doses of esketamine. The most frequent adverse effects under treatment with esketamine were nausea, dissociation, dizziness, vertigo, hypoesthesia, sedation and paresthesia. Therefore, when determining the administration of esketamine, potential adverse effects should be considered.

**Acknowledgements** It is grateful to everyone who has taken part in the research on esketamine for MDD.

**Availability of Data and Material** Not applicable.

**Authors’ Contributions** Xinmin Zhou and Xiang Xu were the principal investigators. Siyuan Yang and Jiahe Wang designed the research and make the protocol for study. Xiang Li and Zhongmou Xu analyzed the data and performed meta-analysis. Tianyi Wang, Siyuan Yang and Jiahe Wang contributed to writing the article. Siyuan Yang, Jiahe Wang and Gang Chen revised the article format and the language.

**Funding** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Compliance with Ethical Standards**

**Conflicts of Interest/Competing Interests** The authors declare that they have no conflict of interest.

**Ethics Approval** Not applicable.
Consent to Participate  Not applicable.

Consent for Publication  Not applicable.

Informed Consent  NA.

Code Availability  Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Amidfar M, Réus GZ, Quevedo J, Kim YK. The role of memantine in the treatment of major depressive disorder: clinical efficacy and mechanisms of action. Eur J Pharmacol. 2018;827:103–11. https://doi.org/10.1016/j.ejphar.2018.03.023.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. https://doi.org/10.1371/journal.pmed.0030442.
3. Kuperberg A, Bicks L, Hasler G. Social functioning in major depressive disorder. Neurosci Biobehav Rev. 2016;69:313–32. https://doi.org/10.1016/j.neubiorev.2016.07.002.
4. Cuipers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord. 2002;72(3):227–36. https://doi.org/10.1016/s0165-0327(01)00413-x.
5. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. https://doi.org/10.1001/archpsyc.62.6.593.
6. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–57. https://doi.org/10.1016/s0140-6736(06)68770-9.
7. Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal Esketamine adjunctive to Oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2018;75(2):139–48. https://doi.org/10.1001/jamapsychiatry.2017.3739.
8. Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose Esketamine nasal spray combined with a new Oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–30. https://doi.org/10.1093/ijnp/pyz039.
9. Tibensky BN, de Léséleuc L, Perras C, Picheca L. Esketamine for Treatment-Resistant Depression. CADTH Issues in Emerging Health Technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Copyright © CADTH 2019. You are permitted to reproduce this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH.; 2016. p. 1–17.
10. Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and safety of intranasal Esketamine for the rapid reduction of symptoms of depression and Suicidality in patients at imminent risk for suicide: results of a double-blind, randomized. Placebo-Controlled Study Am J Psychiatry. 2018;175(7):620–30. https://doi.org/10.1176/appi.ajp.2018.17060720.
11. Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sánchez E, Gutiérrez-Rojas L, Meana JJ. Antidepressant efficacy and tolerability of ketamine and Esketamine: a critical review. CNS Drugs. 2018;32(5):411–20. https://doi.org/10.1007/s40263-018-0519-3.
12. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, et al. Intravenous Esketamine in adult treatment-resistant depression: a double-blind, double-randomization. Placebo-Controlled Study Biol Psychiatry. 2016;80(6):424–31. https://doi.org/10.1016/j.biopsych.2015.10.018.
13. Smith-Apeldoorn SY, Verraart JKE, Kamphuis J, van Asselt ADI, Touw DJ, Aan Het Rot M, et al. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. BMC Psychiatry. 2019;19(1):375. https://doi.org/10.1186/s12888-019-2359-1.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Siyuan Yang is a master in the department of Clinical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China and major in neurological sciences.

Jiahe Wang is a master in the department of Clinical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China and major in neurological sciences.

Xiang Li is a doctor in the department of Clinical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China and major in neurological sciences.

Tianyi Wang is a doctor in the department of Clinical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China and major in neurological sciences.

Zhongmou Xu is a doctor in the department of Clinical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China and major in neurological sciences.

Xiang Xu is a doctor in the department of Clinical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China and major in neurological sciences.

Xinmin Zhou is a MD in the department of Clinical Medicine, The Affiliated Jiangyin Hospital, School of Medicine, Southeast University, Jiangyin, Jiangsu Province, China and major in neurological sciences.

Gang Chen is MD PHD in the department of Clinical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China and major in Neurological sciences.

Affiliations

Siyuan Yang\(^1\) · Jiahe Wang\(^1\) · Xiang Li\(^1\) · Tianyi Wang\(^1\) · Zhongmou Xu\(^1\) · Xiang Xu\(^1\) · Xinmin Zhou\(^2\) · Gang Chen\(^1\)

\(^1\) Department of Clinical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

\(^2\) Department of Clinical Medicine, The Affiliated Jiangyin Hospital, School of Medicine, Southeast University, Jiangyin, Jiangsu Province, China